Assessment of alterations in IFN-g and IL-17 levels in COVID-19 patients
DOI:
https://doi.org/10.48047/mc5g3205Keywords:
Corona virus 2019, SARS, IFN gama, IL-17 levels, NRL, LYM, WBCAbstract
The current thesis aims to examine changes in IFN gama and IL-17 levels in coronavirus patients in order to identify the most effective techniques for following up with patients and, as a result, offering the best medicines in the shortest amount of time. NRL, LYM, and WBC exhibited evident substantial alterations that might be utilized to detect the disease early or to monitor the
patient's condition by comparing them to other blood parameters with unique differences. IFN-g, assessed by an operational immunoassay, was studied as an indicator for the likelihood of hospital throughout the initial phases of illness as well as one month following infection. Low concentrations of IFN-g and IL-17 were associated with higher hospitalization rates (p<0.001).
The study's main goal was to learn more about the function of mediation in COVID-19 patients. Cytokines like IFN-γ and IL-17 were found to be elevated in patients infected with SARS-CoV-2. These cytokines are crucial markers of sickness severity and could be utilized as therapeutic targets.
Downloads
References
-McMichael, T. M., Currie, D. W., Clark, S., Pogosjans, S., Kay, M., Schwartz, N. G. and Duchin, J. S. 2020. Epidemiology of COVID-19 in a long-term care facility in King County, Washington. New England Journal of Medicine, 382(21): 2005-2011.
-Munster, V. J., Koopmans, M., van Doremalen, N., van Riel, D. and de Wit, E. 2020. A novel coronavirus emerging in China key questions for impact assessment. New England Journal of Medicine, 382(8): 692-694
Downloads
Published
Issue
Section
License
This work is licensed under a Creative Commons Attribution 4.0 International License.
You are free to:
- Share — copy and redistribute the material in any medium or format for any purpose, even commercially.
- Adapt — remix, transform, and build upon the material for any purpose, even commercially.
- The licensor cannot revoke these freedoms as long as you follow the license terms.
Under the following terms:
- Attribution — You must give appropriate credit , provide a link to the license, and indicate if changes were made . You may do so in any reasonable manner, but not in any way that suggests the licensor endorses you or your use.
- No additional restrictions — You may not apply legal terms or technological measures that legally restrict others from doing anything the license permits.
Notices:
You do not have to comply with the license for elements of the material in the public domain or where your use is permitted by an applicable exception or limitation .
No warranties are given. The license may not give you all of the permissions necessary for your intended use. For example, other rights such as publicity, privacy, or moral rights may limit how you use the material.
